As for the p53-MDM2 pathway, when the p16 methylation status was compared with the p53 and MDM2 protein expression in ESCC patients, we observed that ESCC tumors with p16 epigenetic inactivation more often harbored increased levels of p53 protein expression. The gene discussed is MDM2; the disease is esophageal squamous cell carcinoma.